Sakar Healthcare Limited (SAKAR) — Financial Results Announcement
Revenue: ₹7,110 CrNet Profit: ₹1,024.91 Cr
📢 Key Event
Sakar Healthcare disclosed audited Q4FY26 financial results showing 42% YoY revenue growth to ₹7,110 lakhs and 67% YoY EBITDA growth to ₹2,624 lakhs.
🔄 What Changed
67% YoY EBITDA growth to ₹2,624 lakhs and 12 new oncology marketing authorizations
🔮 What's Next
FY27 growth expected from oncology ramp-up and improved export traction
💡 Investor Takeaway
Oncology growth is driving margin expansion and future profitability improvement for shareholders.
Sakar Healthcare reported consolidated revenue of **₹7,110 lakhs** for Q4FY26, up 42% YoY, driven by oncology growth and new market authorizations. EBITDA rose 67% YoY to **₹2,624 lakhs**, with margin expanding to 37%, while PAT margin improved to 16%. The company highlighted 12 marketing authorizations for oncology products and ongoing technology transfers with global partners as key catalysts for FY27 momentum.
📄 View Original Announcement (PDF)
About Sakar Healthcare Limited (SAKAR)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,550.15 Cr
P/E: 102.3
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.